NCT06790290View on ClinicalTrials.gov

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

421

Participants

Timeline

Start Date

January 27, 2025

Primary Completion Date

April 3, 2025

Study Completion Date

December 31, 2026

Conditions
Pneumococcal Disease, Invasive
Interventions
BIOLOGICAL

Formulation B

IVT PCV-25

BIOLOGICAL

Formulation C

IVT PCV-25

BIOLOGICAL

Formulation D

IVT PCV-25

BIOLOGICAL

Prevnar20

20 valent pneumococcal conjugate vaccine

Trial Locations (3)

Unknown

Health Index Multispecialty Clinic, Bacoor

Grand Centennial Homes Clinic, Kawit

University of the Philippines-National Health Institute_Doña Nena Health Center, Pasay

Sponsors

Lead Sponsor

Inventprise Inc.
All Listed Sponsors
collaborator

University of the Philippines-National Health Institute_Doña Nena Health Center

UNKNOWN

collaborator

Health Index Multispecialty Clinic

UNKNOWN

collaborator

Grand Centennial Homes Clinic

UNKNOWN

lead

Inventprise Inc.

INDUSTRY

NCT06790290 - Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants | Biotech Hunter | Biotech Hunter